ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European ...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …